OMNIAB INC
OABINASDAQTrading Snapshot
- Day Range
- $4.91 – $5.29
- 52-Week Range
- $1.30 – $5.43
- Volume (shares)
- 1,582,653
- Avg Volume (shares)
- —
- Shares Outstanding
- 145.4M
- Next Earnings
- 2026-10-30
Fundamentals Snapshot
- Annual Revenue
- $19M
- Last Q Revenue
- $13M
- P/E Ratio
- —
- P/S Ratio
- 18.8x
- EPS (TTM)
- $-0.36
- Dividend Yield
- —
- Dilution (1yr)
- +21.9%
OMNIAB INC
OABI
StockOtter · stockotter.spaceAbout OMNIAB INC
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
OmniAb to Participate in Upcoming Investor Conferences in November
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced manageme
OmniAb Highlights $3B Milestone Pipeline, AI Antibody Platform at Conference
OmniAb NASDAQ: OABI Chief Financial Officer Kurt Gustafson outlined the company's antibody-discovery platform, partner pipeline and revenue model during a company presentation, emphasizing a strategy built around licensi
OmniAb to Report Third Quarter 2026 Financial Results on October 30
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Comp
OmniAb Investor Day Spotlights Royalty Pipeline, OmniTides Launch and xPloration Growth
OmniAb NASDAQ: OABI used its investor and analyst day to outline its strategy for expanding royalty-bearing partnerships, commercializing its xPloration screening platform and entering the peptide-discovery market throug
OmniAb, Inc. (OABI) Analyst/Investor Day Transcript
OmniAb, Inc. (OABI) Analyst/Investor Day Transcript
All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy
OmniAb, Inc. (OABI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.